Navigation Links
Case Western Reserve awarded $4.7 million from Defense Advanced Research Projects Agency
Date:7/30/2010

CLEVELAND July 30, 2010 Jonathan Stamler, MD, Director of the Institute for Transformative Molecular Medicine and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at the Case Western Reserve University and University Hospitals Harrington-McLaughlin Heart & Vascular Institute, has recently received a $4.7 million contract from the Defense Advanced Research Projects Agency (DARPA) to fund the development of a new class of drugs that will selectively dilate blood cells under hypoxia (lack of oxygen in the body's tissues) and thereby enhance soldiers' performance at high altitude.

"Our blood carries less oxygen at high altitudes," said Dr. Stamler. "And there is not much we can do about it. But if we could improve blood flow in tissues we could deliver more oxygen regardless of how much oxygen the blood carries."

Development of any method to enhance tissue oxygenation at high altitudes must consider the distinction between blood O2 content (how much oxygen the blood carries) and red blood cell (RBC) O2 delivery (primarily a function of blood flow). Oxygen delivery is controlled by a gas called nitric oxide, which is released from RBCs under hypoxia. Nitric oxide dilates blood vessels and thereby improves blood flow.

It's anticipated that the grant will generate new physiologic information on high-altitude adaption and new therapeutic interventions to treat patients suffering from conditions where oxygen delivery is impaired, including heart failure, ischemic heart disease, stroke, sickle cell disease and diabetes.

The study will involve a transdisciplinary team including the department of anesthesia, the division of pulmonary medicine, and the Harrington-McLaughlin Cardiovascular Institute at University Hospitals Case Medical Center, Case Western Reserve School of Medicine's primary clinical affiliate.


'/>"/>

Contact: Christina DeAngelis
christina.deangelis@case.edu
216-368-3635
Case Western Reserve University
Source:Eurekalert

Page: 1

Related biology news :

1. UT Southwestern researchers use novel sperm stem-cell technique to produce genetically modified rats
2. Temperature and salt levels of the Western Mediterranean are on the increase
3. UT Southwestern researchers find mechanism that may stop E. coli from developing in cattle
4. UT Southwestern researchers identify key molecular step to fighting off viruses
5. Case Western Reserve team discovers smart insulin molecule
6. UT Southwesterns BioCenter driving biotech, medical innovation in North Texas
7. New brain nerve cells key to stress resilience, UT Southwestern researchers find
8. UT Southwestern student receives fellowship from Howard Hughes Medical Institute
9. UT Southwestern researchers find clues to TB drug resistance
10. American pika are thriving in the Sierra Nevada and southwestern Great Basin
11. Plant breeding helps revive western rangelands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/12/2017)... 2017 A new report by Allied Market Research, titled, "Global ... technology market is expected to generate revenue of $10.72 billion by 2022, with an ... Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) In the year ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... ... ... Nipro Corporation (Osaka, Japan) and Transonic Systems Inc. (New York, USA) announced ... and sales rights for all non-OEM Transonic products in Japan. As partners for more ... Nipro - Transonic JV is a natural next step to advance best practices and ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, today presented ... compound, napabucasin, at the 2017 American Society of Clinical ... Francisco . In a Phase ... agent designed to inhibit cancer stemness pathways by targeting ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... Surgery (LES®) Technologies, announced today the next evolution in spinal fusion, the ... platform). In contrast to the competition, SpineFrontier is focused on technique driven ...
(Date:1/19/2017)... 19, 2017 Research and Markets ... has announced the addition of the ... Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market trends ... using estimated market values as the base numbers Key ...
Breaking Biology Technology: